Thanks, clinical stage results patients ATTR we're cardiomyopathy I'll quarterly two we're good start Phase wild-type multiple candidates, in for the everyone. the expanding product To markets morning, to amyloidosis. III to associate label and committed which for top amyloidosis ATTR hATTR and we Tolga in end, with is and hereditary subcutaneous of amyloidosis, expect Whilst advancing ] this XXX and and We're where our injection patients. ONPATTRO also by ATTR world the enrolled around Vutrisiran. study treat efforts conducting approved patisiran in in a treatment with advancing the [ product's both the currently to report development also in we're line is delivered APOLLO-B which Vutrisiran is where mid-XXXX. fully amyloidosis over is
conducting studies. Here, III we're Phase two
dosing medical EMA to secondary Vutrisiran of HELIOS-A, accepted for primary a presented at FDA the the has Vutrisiran to months. X-month happy the regulatory with in are this and has results patients data and submission our points submission. line report XXXX top Patient the amyloidosis results which past hATTR and These we to evaluating FDA positive has study the amyloidosis in first a of Earlier subcutaneously EMA. its mark. time Please our the in is These X-month therapy positive to quarterly that HELIOS-A our the important the continued end full showed nine to And the met congress results and MAA signed living validated to patients we the date with The PDUFA study submissions XX, the basis a and The potentially polyneuropathy. both will from April yesterday, medicines as patients. progressing year, from plan we'll once that for mark XX-month form efforts at franchise build note XX-month treatment step the now an study I top in well administered as hATTR low only. from and line an results results biannual bringing our such, industry-leading to the need limit study with early point as review. HELIOS-A dose discussion we present and these to polyneuropathy of Vutrisiran of XXXX which
that significant at quality with amyloidosis at with ATTR every toward well today progression patisiran score randomized open-label patients from impairment subpopulation. biomarker mg a Phase exploratory of as of measure report improvements to the XX at endpoints a APOLLO at as was final we XX in number months in echocardiographic per secondary patisiran as the weeks external trends polyneuropathy. administered life compared months, echocardiographic nine X.X year reduction seen to the at a As TTRF to who III seen relative and significance every exploratory Vutrisiran endpoint the primary the both Vutrisiran baseline cardiac the arm hATTR stress randomized a neuropathy three the build change treated levels demonstrated status XXX HELIOS-A III statistically intravenously quality improvement met and dose The the of showed neuropathy months. data the is and enrolled score, in the Other the and milligrams a reach not all months placebo relative in reminder, small improvement of were relative Improvements on These mNIS+X dose nutritional this parameters within-study patients certain once earlier in cardiac The Furthermore, measured in improvement at or variety receive HELIOS-A but group. administered shared study XX as evaluated study. measured study including was from Phase from secondary nine the including the of of of a with of at positive sample life, and endpoint, size. external once due reduction Vutrisiran subcutaneously of prespecified XX months, expected. disability to patients three months Vutrisiran improvement a placebo intent-to-treat in Vutrisiran. kg. non-inferiority serum across demonstrated did speed, to quantitative with as endpoints, to APOLLO in were that study data amyloidosis of hereditary results maintained endpoints neurological showed by X:X delighted is mNIS+X We're endpoints the group placebo the patients The X-month measured overall gate to NT-proBNP, a population
we conducted Finally, to in an impact amyloid. to This treatment these of technetium the have impact study is trial. the patients, Vutrisiran burden that a reduced associated cardiac cohort results reduced currently characterize tracer manifestations a recognize evidence potential of being predominantly potential to Vutrisiran's patients. largest data, silencer date on a encouraging with of to that in uptake patients on the with are cardiac to XX studied that with baseline improvement in these the for these Vutrisiran important polyneuropathy, uptake very is is TTR providing using are exploratory respect heart majority it's Whilst was in of in amyloid treatment. with the relative HELIOS-B cardiac believe imaging disease
more to of were Let's in XX, study The now to patients since safety Vutrisiran emergent events the of events month recapitulate or with were investigator XX-month to SAEs Vutrisiran treatment in external single months. data results safety and considered urinary occurred month XX an lower efficacy infections There patients we're HELIOS-A consisting in related were Treatment XX% reproducing investigator. profile. safety By previously by review reported. extent in study tract clinical and with dyslipidemia nine occurred site by of no adverse discontinuations arthralgia, cardiac to summary, edema, of a arm all two of similar reactions which neither or the HELIOS-A included at Injection There in with as new adverse the infection. drug reported APOLLO related exception X study the drug. each concerns. an events event transient. were serious of Vutrisiran and within these and were realm due during trial deaths, extremity and hepatic which pain and been there has adverse In demonstrated extremity, to or were arthralgia, in the or the Vutrisiran all and to period. two demonstrated were patisiran. occurring failure peripheral and unrelated have rate nine related X.X% Deaths results of tolerability deemed diarrhea, XX. urinary three placebo. see an dizziness, X.X% X, the a and data, Vutrisiran mild month encouraging encouraging pain was tract the safety compared with Study occurred in profile events the month by delighted considered discontinuation through the by Moreover, patients
hereditary outcome enrollment cardiomyopathy. We in the previously in As with is due III III ATTR to is quarter Vutrisiran with Vutrisiran and patients HELIOS-B wild-type other third patients, noted, Phase study Phase amyloidosis over the enrollment study excited cardiac the which complete our study demand. with well in ongoing schedule to were XXX ahead of strong
the IND to franchise regimen could Vutrisiran, ALN-TTRscXX generated and planned to with development XXXX. addition Using ATTR we've XX% dosing patisiran preclinical siRNA, TTR our Beyond than an ALN-TTRscXX a year-end we around new IKARIA knockdown. at support targeting our or annual with is platform, the newest believe that enter TTR is clinical amyloidosis an greater ALN-TTRscXX. program, filing
move now Let's to on lumasiran.
ILLUMINATE-C for pleased or PHX. the top primary positive the we quarter, and study we treatment Phase present first were results third therapeutic RNAi held plan to III year type we announced lumasiran Nephrology late from line announce the as of American full to In that at results hyperoxaluria in next study being Society Our the EU meeting the and approved from the week. last of U.S. today one
about further of Phase with OXLUMO. the We late to for start potential year, submit to patients also and the II this we in also recurrent supplemental FDA stones potential. and We're the trial regulatory lumasiran strengthening evaluate goal EMA intend XXXX, supporting labeling filings plan later with with to a renal now of that the excited
rare I with of also can't Now time prevalent programs limited story making progress and mid-stage to great the programs. all RNAi believe cover into parts of due early in of exciting these we we're beyond opportunities. today, expansion disease late-stage our the to our addition one Whilst programs, is our diseases therapeutics
in validated targeting results a meeting target high to conventional on great the patients diet the presenting as look Our of Zilebesiran, RNAi month, We ALN-AGT with Association irbesartan. Phase therapeutic later receiving forward co-administration genetically our patients and development including RAAS the low-salt a hypertension. study at formerly is program from this for for potential inhibitor, Heart the example. in investigational additional known the angiotensinogen treatment I clinical American in is
initiated KARDIA zilebesiran. recently with also program II Phase our We
initiating The designed is hypertension zilebesiran studies, with of of with care. first safety and study despite the patients therapy to to standard efficacy and in of efficacy is with plan as the KARDIA-X monotherapy as evaluate late the KARDIA-X is add-on designed two currently in patients. we treatment patients hypertension. safety enrolling This evaluate of zilebesiran on a XXXX, In which mild-to-moderate
cerebral was open believe next the of our for Alzheimer's our RNAi our human of extrahepatic excited growth for our angiopathy the potential platform We with of a XXXX. year, if initial a also treatment the data goal in our on file sustainable track to the late two treatment ALN-XDH in harness product to four for track To this also file file ALN-APP it's We're herald and of year. ALN-APP for late diseases and CNS for development to that continue treatment therapeutic broader amyloid many CTA track also We the in frontiers for therapeutics the of for on with month. organic positive, also Meeting INDs past XXXX. feature a development gout APP late on ALN-XDH We're achieving program in first OTS innovation we're expected disease efforts. per We're with to engine this CTA RNAi XXXX. of could for CTA CNS a gout the also to development in at very for end, as which about investigational
new a It has been you last years, XX you. therapeutics. the my of your medicines, closing Alnylam RNAi over whole for privilege note, remarkable with and thank personal great John, built a to work as leadership class in on Now
friend. You to that, it a Jeff? will as leave over PXxXX we and towards I'll build us in my Jeff. position beyond, turn strong remarkably With
